Long-term Results of Treatment with Bosentan in Adult Eisenmenger's Syndrome Patients with Down's Syndrome Related to Congenital Heart Disease

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2013 Sep 20

PMID 24047157

Citations 14

Authors

Roberto Crepaz

Cristina Romeo

Donato Montanaro

Stefano De Santis

Affiliations

Soon will be listed here.

Abstract

Background: Patients with Down's syndrome and shunt lesions are at high risk of developing pulmonary arterial hypertension (PAH) earlier than patients without Down's syndrome. However, data on the efficacy of PAH-specific therapy in patients with Down's syndrome are limited. The aim of this retrospective analysis was to determine the long-term efficacy of the dual endothelin receptor antagonist, bosentan, in Eisenmenger's syndrome (ES) patients with Down's syndrome.

Methods: In this observational study adults with Down's syndrome with a confirmed diagnosis of ES (World Health Organization functional class III) and receiving bosentan therapy and were followed up long term. Clinical evaluation at baseline and follow-up visits included resting transcutaneous arterial oxygen saturation and laboratory assessments. Exercise capacity was evaluated using a 6-minute walk test where transcutaneous arterial oxygen saturation at peak exercise (SpO2), 6-minute walk distance (6MWD) and Borg dyspnoea index were assessed. A full echocardiographic assessment was conducted at baseline and follow-up visits.

Results: Overall, seven adults (mean age 29.6 ± 11.2 years; 57% male) received bosentan at a starting dose of 62.5 mg twice daily. This was increased to the target dose of 125 mg twice daily 4 weeks later. All patients remained on bosentan until the end of the study. After a mean (± standard deviation) duration of 52.2 ± 3.9 months (range: 46.0-55.5 months), 6MWD had increased from 199.6 ± 69.1 metres to 303.7 ± 99.9 metres (P < 0.05) and SpO2 at the end of the 6-minute walk test had increased from 61.6 ± 7.6% to 74.7 ± 6.2% (P < 0.05). Echocardiography demonstrated a significant change in acceleration time from 62.9 ± 11.6 m/s to 83.0 ± 9.6 m/s (P = 0.0156), and acceleration time/ejection time ratio from the pulmonary flow from 0.24 ± 0.04 at baseline to 0.30 ± 0.02 (P = 0.0156) at final follow-up.

Conclusions: Long-term treatment with bosentan significantly improved exercise capacity and oxygen saturation following exercise in adult ES patients with Down's syndrome. These data confirm that the presence of Down's syndrome does not affect the response to oral bosentan therapy.

Citing Articles

Cardiovascular Diseases in Public Health: Chromosomal Abnormalities in Congenital Heart Disease Causing Sudden Cardiac Death in Children.

Salzillo C, La Verde M, Imparato A, Molitierno R, Luca S, Pagliuca F Medicina (Kaunas). 2025; 60(12.

PMID: 39768857 PMC: 11679308. DOI: 10.3390/medicina60121976.

Outcome of Down patients with repaired versus unrepaired atrioventricular septal defect.

Daene M, De Pauw L, De Meester P, Troost E, Moons P, Gewillig M Int J Cardiol Congenit Heart Dis. 2024; 12:100452.

PMID: 39711818 PMC: 11658211. DOI: 10.1016/j.ijcchd.2023.100452.

Long-term course of pulmonary arterial hypertension in adults with congenital heart disease under targeted therapy: a retrospective analysis of a single tertiary center.

Strack K, Freilinger S, Busse A, Ewert P, Hauser M, Huntgeburth M Cardiovasc Diagn Ther. 2022; 12(5):655-670.

PMID: 36329967 PMC: 9622403. DOI: 10.21037/cdt-22-266.

The Consistent Effectiveness and Safety of Macitentan Therapies Across Idiopathic and Congenital Heart Disease-Associated PulmonaryArterial Hypertension: A Single-Center Experience.

Kaymaz C, Tanyeri S, Tokgoz H, Akbal O, Karagoz A, Keskin B Anatol J Cardiol. 2022; 26(10):778-787.

PMID: 36196862 PMC: 9623128. DOI: 10.5152/AnatolJCardiol.2022.1889.

Efficacy and safety of pulmonary vasodilators in the patients with Eisenmenger syndrome: a meta-analysis of randomized controlled trials.

Hou Y, Wen L, Shu T, Dai R, Huang W Pulm Circ. 2021; 11(2):20458940211015823.

PMID: 34164108 PMC: 8191088. DOI: 10.1177/20458940211015823.

References

Chi TPLKrovetz J . The pulmonary vascular bed in children with Down syndrome. J Pediatr. 1975; 86(4):533-8. DOI: 10.1016/s0022-3476(75)80142-9. View

Galie N, Beghetti M, Gatzoulis M, Granton J, Berger R, Lauer A . Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006; 114(1):48-54. DOI: 10.1161/CIRCULATIONAHA.106.630715. View

Penning S, Robinson K, Major C, Garite T . A comparison of echocardiography and pulmonary artery catheterization for evaluation of pulmonary artery pressures in pregnant patients with suspected pulmonary hypertension. Am J Obstet Gynecol. 2001; 184(7):1568-70. DOI: 10.1067/mob.2001.114857. View

Vis J, Thoonsen H, Duffels M, de Bruin-Bon R, Huisman S, van Dijk A . Six-minute walk test in patients with Down syndrome: validity and reproducibility. Arch Phys Med Rehabil. 2009; 90(8):1423-7. DOI: 10.1016/j.apmr.2009.02.015. View

Bossone E, Avelar E, Bach D, Gillespie B, Rubenfire M, Armstrong W . Diagnostic value of resting tricuspid regurgitation velocity and right ventricular ejection flow parameters for the detection of exercise induced pulmonary arterial hypertension. Int J Card Imaging. 2001; 16(6):429-36. DOI: 10.1023/a:1010604913656. View

Galie N, Hoeper M, Humbert M, Torbicki A, Vachiery J, Barbera J . Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the.... Eur Heart J. 2009; 30(20):2493-537. DOI: 10.1093/eurheartj/ehp297. View

Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R . The Belgian Eisenmenger syndrome registry: implications for treatment strategies?. Acta Cardiol. 2009; 64(4):447-53. DOI: 10.2143/AC.64.4.2041608. View

DAlto M, Vizza C, Romeo E, Badagliacca R, Santoro G, Poscia R . Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart. 2006; 93(5):621-5. PMC: 1955562. DOI: 10.1136/hrt.2006.097360. View

Elmagrpy Z, Rayani A, Shah A, Habas E, Aburawi E . Down syndrome and congenital heart disease: why the regional difference as observed in the Libyan experience?. Cardiovasc J Afr. 2011; 22(6):306-9. PMC: 3721875. DOI: 10.5830/CVJA-2010-072. View

10.

Suzuki K, Yamaki S, MIMORI S, Murakami Y, Mori K, Takahashi Y . Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect. Am J Cardiol. 2000; 86(4):434-7. DOI: 10.1016/s0002-9149(00)00960-7. View

11.

Vis J, Duffels M, Mulder P, de Bruin-Bon R, Bouma B, Berger R . Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2011; 164(1):64-9. DOI: 10.1016/j.ijcard.2011.06.064. View

12.

Diaz-Caraballo E, Gonzalez-Garcia A, Renones M, Sanchez-Recalde A, Garcia-Rio F, Oliver-Ruiz J . Long-term bosentan treatment of complex congenital heart disease and Eisenmenger's syndrome. Rev Esp Cardiol. 2009; 62(9):1046-9. DOI: 10.1016/s1885-5857(09)73271-2. View

13.

Kaya M, Lam Y, Erer B, Ayhan S, Vatankulu M, Nurkalem Z . Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail. 2012; 18(5):379-84. DOI: 10.1016/j.cardfail.2012.02.004. View

14.

Kermeen F, Franks C, OBrien K, Seale H, Hall K, McNeil K . Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. Heart Lung Circ. 2010; 19(10):595-600. DOI: 10.1016/j.hlc.2010.07.005. View

15.

DAlto M, Romeo E, Argiento P, DAndrea A, Sarubbi B, Correra A . Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. Int J Cardiol. 2011; 164(3):323-6. DOI: 10.1016/j.ijcard.2011.07.009. View

16.

Sherman S, Allen E, Bean L, Freeman S . Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev. 2007; 13(3):221-7. DOI: 10.1002/mrdd.20157. View

17.

Serino G, Guazzi M, Micheletti A, Lombardi C, Danesi R, Negura D . Effect of bosentan on exercise capacity and clinical worsening in patients with dual down and eisenmenger syndrome. Clin Med Insights Cardiol. 2013; 7:29-34. PMC: 3572875. DOI: 10.4137/CMC.S10237. View

18.

Monfredi O, Griffiths L, Clarke B, Mahadevan V . Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Am J Cardiol. 2011; 108(10):1483-8. DOI: 10.1016/j.amjcard.2011.07.006. View

19.

Chehab G, El-Rassi I, Abdo A, Fakhoury H, Chokor I, Haddad W . [Atrioventricular septal defect characteristics in infants with and without Down's syndrome: a Lebanese study]. J Med Liban. 2010; 58(1):3-7. View

20.

Placidi S, Digilio M, Marino B . Types of cardiac defects in children with Down's syndrome. Cardiol Young. 2006; 16(2):198-9. DOI: 10.1017/S1047951106220225. View